ATE154245T1 - Verfahren zur zellwachstumshinderung und dazu nützliche verbindungen - Google Patents

Verfahren zur zellwachstumshinderung und dazu nützliche verbindungen

Info

Publication number
ATE154245T1
ATE154245T1 AT91907581T AT91907581T ATE154245T1 AT E154245 T1 ATE154245 T1 AT E154245T1 AT 91907581 T AT91907581 T AT 91907581T AT 91907581 T AT91907581 T AT 91907581T AT E154245 T1 ATE154245 T1 AT E154245T1
Authority
AT
Austria
Prior art keywords
cell growth
combinations
combination
individually
inhibiting cell
Prior art date
Application number
AT91907581T
Other languages
English (en)
Inventor
Ian Stuart Trowbridge
Raymond Taetle
Suhaila Nakhoul White
Original Assignee
Salk Inst For Biological Studi
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Inst For Biological Studi, Univ California filed Critical Salk Inst For Biological Studi
Application granted granted Critical
Publication of ATE154245T1 publication Critical patent/ATE154245T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
AT91907581T 1990-03-27 1991-03-26 Verfahren zur zellwachstumshinderung und dazu nützliche verbindungen ATE154245T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50003590A 1990-03-27 1990-03-27

Publications (1)

Publication Number Publication Date
ATE154245T1 true ATE154245T1 (de) 1997-06-15

Family

ID=23987769

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91907581T ATE154245T1 (de) 1990-03-27 1991-03-26 Verfahren zur zellwachstumshinderung und dazu nützliche verbindungen

Country Status (8)

Country Link
US (1) US5667781A (de)
EP (1) EP0525005B1 (de)
JP (1) JPH05505823A (de)
AT (1) ATE154245T1 (de)
AU (1) AU642014B2 (de)
CA (1) CA2081368A1 (de)
DE (1) DE69126526T2 (de)
WO (1) WO1991014452A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69428041T2 (de) * 1993-05-03 2002-03-28 Genentech, Inc. Inhibierung von Leukozytenadhäsion
US5922346A (en) * 1997-12-01 1999-07-13 Thione International, Inc. Antioxidant preparation
US20020199218A1 (en) * 1999-08-19 2002-12-26 Daphne Goring Proline-rich extensin-like receptor kinases
CA2364983A1 (en) * 2000-12-13 2002-06-13 John R. Coleman Nucleic acid molecules and polypeptides for catabolism of abscisic acid
US7597895B2 (en) * 2001-02-20 2009-10-06 The Governing Council Of The University Of Toronto Signal peptides, nucleic acid molecules and methods for treatment of caries
US7556807B2 (en) 2001-02-20 2009-07-07 Kane Biotech, Inc. Signal peptides, nucleic acid molecules and methods for treatment of caries
WO2004094647A2 (en) * 2003-04-18 2004-11-04 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
US6977720B2 (en) * 2003-08-05 2005-12-20 Agilent Technologies, Inc. Characterization of active and passive optical properties of an optical device
WO2005094364A2 (en) * 2004-03-31 2005-10-13 Chimeric Technologies, Inc. Iga antibody protein as a cytotoxic drug
WO2005111082A1 (en) * 2004-04-30 2005-11-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-tfr antibody.
AU2005252699B2 (en) * 2004-06-07 2010-12-23 Macrogenics West, Inc. Transferrin receptor antibodies
US7736647B2 (en) * 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
US9267952B2 (en) 2008-11-05 2016-02-23 Morphosys Ag Deconvolution method
CA2750038C (en) * 2009-02-05 2016-10-04 Oncoxx S.R.L. Anti-trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors
EP2445932B1 (de) 2009-06-26 2018-02-28 Soricimed Biopharma Inc. Soriciden-abgeleitete peptide und verfahren zum nachweisen von trpv-6-krebsarten und medikamentenverabreichung
US8734799B2 (en) * 2010-04-13 2014-05-27 The Regents Of The University Of California Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer
WO2012075037A1 (en) 2010-11-30 2012-06-07 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
CN103534272B (zh) 2011-05-09 2016-05-11 株式会社英仙蛋白质科学 能够特异性识别转铁蛋白受体的抗体
CN102827813B (zh) * 2012-09-30 2014-12-31 苏州大学 抗人cd133单克隆抗体及其制备和应用
CA2893794C (en) 2012-11-08 2021-11-09 University Of Miyazaki Antibody capable of specifically recognizing transferrin receptor
US9499628B2 (en) * 2013-06-14 2016-11-22 Children's Hospital Medical Center Method of boosting the immune response in neonates
JP2018024615A (ja) * 2016-08-10 2018-02-15 学校法人 聖マリアンナ医科大学 Ｈｔｌｖ−１関連炎症性疾患を治療する医薬組成物
US20250115666A1 (en) * 2021-08-05 2025-04-10 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
MX2024002753A (es) 2021-09-01 2024-05-20 Biogen Ma Inc Anticuerpos anti receptor de transferrina y usos de los mismos.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434156A (en) 1981-10-26 1984-02-28 The Salk Institute For Biological Studies Monoclonal antibodies specific for the human transferrin receptor glycoprotein
US4925922A (en) * 1983-02-22 1990-05-15 Xoma Corporation Potentiation of cytotoxic conjugates
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates

Also Published As

Publication number Publication date
US5667781A (en) 1997-09-16
AU642014B2 (en) 1993-10-07
DE69126526D1 (de) 1997-07-17
EP0525005B1 (de) 1997-06-11
JPH05505823A (ja) 1993-08-26
WO1991014452A1 (en) 1991-10-03
EP0525005A4 (en) 1993-06-16
AU7667091A (en) 1991-10-21
CA2081368A1 (en) 1991-09-28
EP0525005A1 (de) 1993-02-03
DE69126526T2 (de) 1998-02-05

Similar Documents

Publication Publication Date Title
DE69126526D1 (de) Verfahren zur zellwachstumshinderung und dazu nützliche verbindungen
ATE124421T1 (de) Verfahren zur wachstumshemmung von stammzellen.
MY108526A (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
DK0627002T3 (da) Kloning og ekspression af humaniserede monoklonale antistoffer mod human interleukin-4
BG99605A (bg) Антагонисти на растежния фактор на ендотелните клетки на кръвоносната система
PT888349E (pt) Pirrolopirimidinas e processos para a sua preparacao
ATE238800T1 (de) Verwendung von squalamin zur herstellung eines arzneimittels zur inhibierung von nhe
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
DK0728194T3 (da) In situ modifikation og manipulation af stamceller fra centralnervesystemet.
DK1113810T3 (da) Fremgangsmåder til behandling af multipelt myelom og myelom-induceret knogleresorption under anvendelse af antagonister af integrin/receptor-binding
DK388384A (da) Monoklone antistoffer med specifitet for membran-associerede antigener, deres fremstilling og anvendelse
FI893428A7 (fi) TNF-a:n in vitro ja in vivo toksisten ominaisuuksien eliminointi monoklonaalisilla vasta-aineilla ja niistä johdetuilla fragmenteilla
DE3684211D1 (de)
DK649689A (da) Fremgangsmaade til eliminering eller inhibering af vaeksten af uoenskede mikroorganismer
PT939809E (pt) Ligandos do receptor de tie-2 (ligando 3 de tie e ligando 4 de tie) e suas utilizacoes
DE3851925D1 (de) Alkylaminalkoxyphenyl-Derivate, Verfahren zur Verwendung und sie enthaltende Zusammensetzungen.
FR2560212B1 (fr) Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
TR199701013T1 (xx) Nitrik oksit synthas'�n�n inhibit�rleri olarak mercapto ve seleno t�revleri.
NO954781L (no) Fremgangsmåter for screening av substanser med en modulerende virkning på en interleukin-5-reseptoravhengig cellulær signaloverföringsvei
DK0504307T3 (da) Fremgangsmåde til behandling af septisk shock
DE69428272D1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
DE69535263D1 (de) Angiotensin ii zur verbesserung der befruchtung
NZ209467A (en) Herbicidal composition derived from phomopsis cirsii and septoria cirsii
DK24891D0 (da) Monoklonalt antistof til inhibering af cellers infektion med hiv-vira
WO1987007302A3 (en) MONOCLONAL ANTIBODIES TO HUMAN LYMPHOCYTE IgE RECEPTORS, HYBRIDOMAS PRODUCING SUCH ANTIBODIES, AND KITS FOR USING SUCH ANTIBODIES

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties